Table 1. Characteristics of subjects.
| Subject ID | Age (years) | Sex | Tumor Size (cm3) | PFS (months) | OS (months) |
|---|---|---|---|---|---|
| Glioblastoma (WHO grade IV) | |||||
| P1* | 61 | M | 13.6 | 6.7 | 16.4 |
| P2 | 55 | M | 4.5 | 13.9 | 35.4 |
| P3 | 58 | M | 8.5 | 0.6 | 0.6 |
| P4* | 43 | M | 90.3 | No recurrence | Survival (44.2) |
| P5 | 79 | F | 30.2 | 8.5 | 11.3 |
| P6 | 83 | M | 81.5 | 8.0 | 11.0 |
| P7 | 68 | F | 25.3 | 6.8 | 22.9 |
| P8 | 71 | M | 10.5 | 9.6 | 21.0 |
| P9 | 64 | M | 21.2 | No recurrence | Survival (38.2) |
| P10* | 70 | M | 50.2 | 3.5 | 8.0 |
| P11 | 80 | F | 31.5 | 16.8 | 21.9 |
| P12 | 54 | M | 55.1 | No recurrence | Survival (36.5) |
| P13 | 61 | M | 20.7 | 8.4 | 15.0 |
| P14 | 60 | M | 13.6 | 10.2 | 24.6 |
| Healthy plasma | |||||
| C1 | 44 | M | |||
| C2 | 42 | M | |||
| C3 | 40 | M | |||
| C4 | 35 | M | |||
| C5 | 32 | M | |||
| C6 | 59 | F | |||
| C7 | 54 | F | |||
| C8 | 34 | F | |||
| C9 | 29 | M | |||
| C10 | 27 | M | |||
| C11 | 30 | M | |||
| C12 | 63 | F | |||
| C13 | 54 | F | |||
| C14 | 34 | M | |||
| C15 | 31 | M | |||
| Noncancerous brain tissue | |||||
| B1 | 56 | F | |||
| B2 | 70 | M | |||
All glioblastoma (GBM) patients had isocitrate dehydrogenase-wildtype. Plasma and tumor tissue samples were obtained from all GBM patients. Cyst fluid samples were obtained from three GBM patients shown in bold with an asterisk (*). The above patient information is as of August 1, 2015. There was a statistically significant difference (p = 4.85×10−6) in age between GBM patients and healthy controls. There was no statistically significant difference in gender between GBM patients and healthy controls. F, female; M, male; OS, overall survival time; PFS, progression-free survival time